We are a pharmaceutical and AI-driven company pioneering next-generation mental health treatments by combining advanced diagnostics with validated, natural anxiolytics to address the urgent global burden of PTSD and anxiety.

AI is accelerating the future of care — enabling real-time screening, 24/7 monitoring, and personalized treatment pathways that deliver measurable improvements in patient outcomes. Our solutions are designed not only to reduce suffering but also to lower healthcare costs, cut lost workdays, and support economic productivity.

Real-World Evidence (RWE) is central to our regulatory strategy. As with the successful development of Covid-19 vaccines and breakthrough oncology medicines, RWE provides a pathway to rapidly bring safe and effective treatments to patients in need.

Albert Labs elevates plant-based remedies into pharma-grade therapies, manufactured under FDA, EMA, and Health Canada standards, while maintaining the gentler safety profile of natural treatments. By validating these therapies with gold-standard science, we aim to disrupt the $400B global nutraceutical and mental health market.

Our NeuroNature LDA and NeuroPath AI platforms deliver treatments that personalize care, accelerate recovery, and integrate seamlessly with existing mental health systems — including DSM-based assessments (such as HADS/GAD-7) and automated insurance reimbursement.

We are a publicly traded company listed on the Canadian Securities Exchange (CSE:ABRT) and Frankfurt Stock Exchange (FSE:VB50).